CPQ Neurology and Psychology (2020) 3:3
Review Article

Neuropsychiatric Manifestations in Relation to SARS-CoV-2 Infection


Juan Enrique Bender del Busto1*, Marcel Mendieta Pedroso, D.2 & Roberto León Castellón3

1Philosopher Doctor, 2nd Degree Specialist in Neurology, Full Professor and Researcher, International Center for Neurological Restoration, Havana, Cuba
22nd Degree Specialist in Integral General Medicine and Internal Medicine, Master in Medical Emergencies in Primary Health Care, Leopoldito Martínez Hospital, San José de las Lajas, Cuba
3Philosopher Doctor, 2nd Degree Specialist in Neurology, General Calixto García University Hospital, Havana, Cuba

*Correspondence to: Dr. Juan Enrique Bender del Busto, Philosopher Doctor, 2nd Degree Specialist in Neurology, Full Professor and Researcher, International Center for Neurological Restoration, Havana, Cuba.

Copyright © 2020 Dr. Juan Enrique Bender del Busto, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 19 June 2020
Published: 29 June 2020

Keywords: Coronavirus; Neuropsychiatric Manifestations; SARS.CoV-2; COVID-19


Abstract

Since Hippocrates, the role of the brain in mental illness has been accepted and Neuropsychiatry has been introduced as the integrating specialty of psychiatry, neurology, neuropsychology, and neuroscience in general. In light of the patients described with the Acute respiratory syndrome in Wuhan, China, which has spread and considered a pandemic, an analytical summary of the scientific evidence available regarding the involvement of the nervous system by the coronavirus 2019 and its impact in the genesis of neuropsychiatric disorders was made. To elaborate it, the Google Academic search engine and the descriptors COVID-19, SARS.CoV-2 and neuropsychiatric manifestations were used. The Medline, Scielo, Scopus and Medscape databases were used. The general clinical manifestations of COVID-19, acute neuropsychiatric symptoms including encephalopathies, epileptic seizures, cerebrovascular disease, myelitis, muscular and peripheral nervous system, taste and smell disorders, and Guillain’s syndrome are described. In addition, subacute or chronic neuropsychiatric sequelae in relation to SARS-CoV-2 infection are highlighted, which include depression, anxiety and stress related to the pandemic, indicating the care to be taken with health personnel, patients with previous mental illness and chronic neurological diseases, in which symptoms can worsen and even lead to suicide.

Introduction
Neuropsychiatry is an integrative medical specialty, combining knowledge and experience in psychiatry with knowledge or experience in neurology / neuroscience and neuropsychology [1].

Since Hippocrates, the role of the brain in mental illness has been accepted. At the dawn of modern scientific medicine in the late 18th and early 19th centuries, physicians identified themselves as neurologists or psychiatrists for reasons that had more to do with the nature and location of the practice than the mindproblem approach. brain. Modern neurology and psychiatry started from a common neuropsychiatric matrix in the late 19th century, which continued to prevail in European training and practice, until, in the last century with the development of neurobiology and other related sciences, they converge again and [2] a new intellectual framework is developed for understanding the brain, healthy and sick, which is a challenge that must be assumed by those who want to lead the field intellectually, and those who must educate others in it [3].

For this reason, it is necessary to analyze the involvement of the nervous system, which includes the neuropsychiatric aspects, from the perspective of the current situation, in which the world is experiencing an extremely stressful scenario since, in the month of December last year, Several patients were reported in Wuhan (Hubei Province, China), with respiratory symptoms and pneumonia, but who, in turn, involved other organs and systems, including the brain. The causal agent was able to specify that it was a new coronavirus (2019-nCoV), which was named in February 2020, coronavirus causing severe acute respiratory syndrome by coronavirus (SARS-CoV-2), constituting the seventh known coronavirus that infects humans [4,5].

Shortly after the disease was named by the World Health Organization (WHO), coronavirus disease 2019 (COVID-19), given its similarity from the virological point of view and also in its clinical expression with SARS-Cov1 (229E (HCoV-229E), responsible for a syndrome with similar characteristics that also originated in the animal markets of China in 2003 [6-8].

In general, coronaviruses that affect humans, and whose origin and possible reservoir are wild animals, including bats, can be classified into those with low pathogenic capacity, which include HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU (Coronavirus α) and those other highly pathogenic, named under the CoV category, such as SARS-CoV (responsible for the 2003 SARS outbreak), along with the one that produced the Middle East Respiratory Syndrome (MERS-CoV) in 2012 and the current year (SARSCoV- 2). These are called Coronavirus β and have become a real public health problem due to their high pathogenicity and infectivity [9].

The outbreak of pneumonia associated with the new coronavirus that was initially reported in Wuhan, [10,11] it caused a rapid increase in the number of cases throughout the region and progressively expanded to various neighboring countries [12,13] and then to Europe and America, declaring a pandemic by the World Health Organization later [14,15].

It has become clear in recent weeks, by multiple authors, that patients infected with the SARS-CoV-2 virus can present in various ways, including neuropsychiatric manifestations, which may precede lung symptoms and fever or present later [16].

This document aims to make an analytical summary of the scientific evidence available regarding the involvement of the nervous system by SARS-CoV-2. To elaborate it, the Google Academic search engine and the descriptors COVID-19, SARS-CoV-2 and neuropsychiatric manifestations / complications were used. The Medline, Scielo, Scopus and Medscape databases were used.

Clinical Manifestations
The main clinical manifestations of COVID-19 are fever, dry cough, dyspnea, and acute respiratory distress. However, many infected subjects may be asymptomatic or present with mild symptoms, such as headache, non-productive cough, fatigue, myalgia, and anosmia. Some patients can experience SARS a week after symptoms start and can be fatal. Overall mortality is estimated at 8% and is due to respiratory failure with hypoxia or multiple organ failure [17].

The infection can also produce interstitial pneumonia and, in many cases, irreversible damage to the lung tissue that generates serious sequelae or leads to death [18].

Elderly or seriously ill patients are the most vulnerable population group. High blood pressure (24%), diabetes mellitus (16%), ischemic heart disease (6%), cerebrovascular diseases (2.3%) and chronic obstructive pulmonary disease (3.5%) are the most frequent comorbidities in severe forms of COVID-19 [17].

Respiratory viruses are also known to penetrate the central nervous system (CNS) (neuroinvasion), affect both neurons and glial cells (a property known as neurotropism), and induce various neurological pathologies (neurovirulence) [19].

Coronavirus infection has been reported in the brains of experimental animals and infected patients [7]. Considering the affinity for the nervous system, SARS-CoV-2 can infect both neurons and neuroglia.

The study of the neurotropic potential of SARS-CoV-2 using pathological samples and its isolation of the endothelium from the cerebral microcirculation, cerebrospinal fluid and brain tissue can further clarify its role in brain damage and its influence on the cardiorespiratory center in the trunk. encephalic [7].

This topic has elicited diverse opinions in the international arena in search of a better definition and to make an alert call to the scientific and practical medical community to be alert to any neuropsychiatric manifestation related to SARS-CoV-2 infection [20].

Acute Neuropsychiatric Symptoms Associated With SARS-CoV-2 Infection
In accordance with the neurotropic properties of SARS-CoV-2, clinical cases are reported from the first studies carried out, where the nervous system affectations of said affection are exposed, which are more frequent in cases of severe infection, worsening the prognosis of patients. [6,15,21,22].

Necropsy studies have shown the presence of hyperemic and edematous brain cell tissue, as well as neuronal degeneration [47,48] and some researchers have detected SARSCoV nucleic acid in the cerebrospinal fluid (CSF) of the patients and in the brain tissue studied [23,24].

In the study of the first affected cases, in the epicenter of Wuhan, China, 214 patients with SARS-CoV-2 were retrospectively evaluated. The most frequent symptoms at the beginning of the disease were fever, dry cough and anorexia. 36.4% of the patients presented neurological manifestations (78 patients), where involvement of the central nervous system (24.8%) predominated, followed by damage to the skeletal muscle (10.7 %) and the peripheral nervous system (8,9 %) [6,12,25].

Among the CNS manifestations, dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and epilepsy were required. The greatest differences between cases of severe and non-severe infection were observed in the deterioration of consciousness and acute cerebrovascular disease (P <0.001 and P <0.05 respectively) [6].

In another series, neurological symptoms or signs were observed in 84%, with the following distribution: confusion (26/40, 65%), agitation (40/58, 69%), signs of the corticospinal tract (39/58, 67%) and dysexecutive syndrome (14/39, 36%) [26].

The severe hypoxia that patients with COVID-19 suffer is a risk factor for encephalopathy [17].

These have been reported as an initial symptom of COVID-19, which can occur in patients with previous neurological damage and acute respiratory symptoms. The risk of suffering an associated altered mental state is higher in people of advanced age or with previous cognitive deterioration, as well as in those who present vascular risk factors (hypertension) and previous comorbidities.

Acute necrotizing hemorrhagic encephalopathy [25], encephalitis [27], and meningoencephalitis have been described, the latter associated with generalized epileptic seizures and decreased level of consciousness [28].

Epileptic seizures were also described in patients with acute stress reaction and hypocalcemia, and in an Iranian study for the first time, their association in the course of coronavirus infection (COVID-19) [29,30].

Ataxia was only reported in the Wuhan study, in a single patient [6] and more recently in one case who presented with acute cerebellar ataxia followed by encephalopathy, who also had SARS-CoV-2-related pneumonia [5].

Cerebrovascular disease was initially reported in the retrospective study of 221 patients with Wuhan COVID-19, presenting 11 (5%) ischemic strokes; one (0.5%), cerebral thrombosis of the venous sinuses; and one (0.5%), a cerebral hemorrhage [31] and has been evidenced in other subsequent studies [12,31-34].

The first case of post-infectious myelitis was reported in a 66-year-old patient diagnosed with COVID-19 [21,25].

Considering the potential of neuromuscular involvement by COVID-19, SARS-CoV-2 infection could cause Guillain-Barré Syndrome, myositis or polyneuropathy / myopathy of the critically ill patient [33].

The infection could also exacerbate a known neuromuscular disease or lead to the diagnosis of one whose symptoms and signs were masked. Among the autoimmune diseases we find: chronic demyelinating inflammatory polyneuropathy (CIDP), multifocal acquired demyelinating sensory-motor neuropathy, multifocal motor neuropathy, Myasthenia Gravis, Eaton-Lambert; and the degenerative group includes: amyotrophic lateral sclerosis, spinal muscular atrophies, hereditary neuropathies, muscular dystrophies, congenital myopathies, mitochondrial, metabolic myopathies, among others [35,36].

Disorders of taste and smell are commonly reported by patients with COVID-19. Recent reports indicate that anosmia or hyposmia are early markers of SARS-CoV-2 infection [37-39].

Some authors found in their casuistry that anosmia or hyposmia was required in 30% of patients. (86). In another case series, 85.6% had infection-related olfactory dysfunction. In another series, the authors specified olfactory dysfunction as the first manifestation of COVID-19 [38,40].

Subacute or Chronic Neuropsychiatric Sequelae in Relation to SARS-CoV-2 Infection

Studies of past respiratory viral pandemics suggest that various types of neuropsychiatric symptoms may arise in the setting of an acute viral infection, or after variable periods of time after infection. Reports from the 18th and 19th centuries suggest that influenza pandemics in particular have been characterized by a higher incidence of various symptoms, such as insomnia, anxiety, depression, mania, psychosis, suicidal tendencies, and delirium [41-43].

The lethargic encephalitis (EL) that was described by Von Economo in 1932, is an inflammatory CNS disorder, characterized by hypersomnia, psychosis, catatonia and parkinsonism, the incidence of which increased at the time of the early “Spanish” influenza pandemic of the 20th century.

During the most recent 2009 influenza (H1N1) pandemic and other coronavirus infections (SARS-CoV-1 epidemic in 2003, and the outbreak of the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, several Neuropsychiatric sequelae, including narcolepsy, epileptic seizures, encephalitis, encephalopathy, Guillain-Barré syndrome (GBS), and other neuromuscular and demyelinating processes [44-47].

In the first months of the current pandemic, reports of acute symptoms associated with the CNS in individuals affected by COVID-19, neurological manifestations and the mechanisms that have been postulated have already been compiled [6].

However, beyond acute infection, the delayed or chronic effects of this pandemic, particularly on mental health, will not be fully appreciated immediately. Therefore, timely and longitudinal investigations of possible neuropsychiatric outcomes associated with COVID-19 are essential in disease surveillance and evidencebased therapeutic strategies [41].

Long-term neuropsychiatric complications after SARS-CoV-2 infection are currently unknown and will be seen in the coming months or years. Following previous influenza pandemics and outbreaks of CoV, such complications have been described for highly variable periods of time, from weeks after acute respiratory symptoms in the case of neuromuscular and demyelinating processes, to decades after intrauterine exposure to viral infection [44,46,48].

Given the overall burden of COVID-19 infection, even if delayed neuropsychiatric sequelae are associated with a fraction of cases, the public health implications of such complications will be significant. Therefore, it is essential to understand the trajectory and characteristics of the neuropsychiatric outcomes derived from SARS-CoV-2 infection, and it will be essential to discover the pathogenic mechanisms that may support therapeutic interventions.

Depression and Anxiety
Depression, anxiety, and trauma-related symptoms of pandemics have been associated with outbreaks of CoV, but it is unclear whether the risks are attributable to viral infections per se or the host’s immune response.

Although currently very limited data exist for COVID-19-related psychiatric symptoms, survivors of SARS-CoV-1 were clinically diagnosed with depression (39%), panic (32.5%), and obsessive-compulsive disorder (15.6%) at 31 to 50 months after infection, a dramatic increase in their pre-infection prevalence of any psychiatric diagnosis by 3% [49].

The main psychiatric manifestations related to the SARS-Cov-2 disease are considered to be due to anxiety, depression and stress. The confinement measures taken to curb the coronavirus, the harshness of the situation for the sick and health, as well as the loss of loved ones in isolation situations have generated severe damage to collective mental health.

Studies of health workers during the SARS-CoV-1 epidemic, the MERSCoV outbreak and the current SARS-CoV-2 pandemic suggest that the frequency and severity of psychiatric symptoms are associated with proximity to patients. infected with CoV [50-53].

It is considered by the authors who have reviewed the topic that the current health crisis represents a great psychological challenge for both health professionals and the population, since COVID-19 infection has compromised social, work and daily life.

Research by Jianbo Lai et al., From the Department of Psychiatry, Renmin Hospital, Wuhan University, evaluated the magnitude of mental health outcomes and associated factors among professionals treating patients exposed to COVID-19 in China. For this, they carried out a cross-sectional study, based on surveys and stratified by regions, which gathered demographic data and psychological well-being evaluations of 1,257 health professionals in 34 hospitals. At the end of the study, the frequent manifestations of mental deterioration in the professionals were identified, which coincided with the manifestations previously mentioned [51].

Some authors consider that health personnel who directly care for patients with COVID-19 acquire stress for fear of becoming infested and this can cause damage to their health. If the psychological adjustment mechanisms do not compensate the situation, they may suffer from Burnout Syndrome (BOS) or posttraumatic stress disorder (PTSD), an entity that has been addressed by many authors, has been described more frequently in the nursing staff [54,55].

A vulnerable group is made up of patients with previous mental entities or those who have suffered special situations capable of developing psychological disorders such as post-traumatic stress, acute stress disorder, major depressive disorder, adaptive disorders or other anxiety disorders, as well as the development of somatic symptoms. In the case of patients suffering from mental pathology prior to infection by this virus, they are at greater risk of relapses or of worsening their symptoms in this situation. The high vulnerability to stress of these people will mean that their suffering may be greater than that of the rest of the population. Some authors even point out that suffering from mental illness increases the risk of contagion [56-60].

On the other hand, the scientific community has been alerted by the Spanish Psychiatric Society, about certain special groups such as patients with an Autism spectrum, patients with intellectual deficit, patients with Alzheimer’s disease who have difficulty in adopting the indicated confinement measures, as well as personal hygiene and protection, suggested by the World Health Organization (WHO). In this sense, patients with schizophrenia may have exacerbation of symptoms and patients with addiction may increase the consumption of drugs such as alcohol, cigarettes, among other harmful substances [61,62].

Psychotic Disorders
Exposure to viral infections in utero, during childhood development, and into adulthood has been associated with an increased risk of developing schizophrenia [43,63,64].

While most studies have focused on the history of influenza and the risk of infection and psychosis, two studies have evaluated the presence of antibodies against various strains of coronavirus in individuals with psychosis. However, no association was reported between seropositivity for HCoV-NL63 and the history of psychotic symptoms in patients with mood disorders [65].

Furthermore, Severance et al found a higher prevalence of antibodies against four strains of HCoV in patients with a recent psychotic episode compared to non-psychiatric controls [66], suggesting a possible relationship between CoV infections and psychosis, which It can also occur in SARS-CoV-2.

Valdés-Florido et al report in the patients admitted to the Virgen del Rocío and Virgen Macarena University Hospitals (Seville, Spain), during the first two weeks of the mandatory quarantine at the national level, four patients who met the criteria for psychotic disorder in the Manual diagnosis and statistics of mental disorders (DSM-5). In the authors’ opinion, all the episodes were triggered by stress arising from the COVID-19 pandemic, and half of the patients exhibited severe suicidal behavior upon admission.

In turn, they consider that we may currently be witnessing an increase in the number of brief reactive psychotic disorders as a result of the COVID-19 pandemic. This type of psychosis, the authors comment, has a high risk of suicidal behavior and, although it is transitory, it has a high rate of psychotic recurrence and low diagnostic stability over time. Therefore, they are in favor of close supervision both in the acute phase and in the long-term follow-up of these patients [67].

In another order, it has been reported that patients with neurological diseases such as multiple sclerosis and other diseases of chronic evolution of the central nervous system, who suffer this nosological entity, can acquire depression, with decreased neurological functions and suffer new damage to the brain. All of which must be taken into account with a view to the comprehensive management of patients [67-69].

Conclusions

• SARS-CoV-2 infection shows evidence of nervous system involvement and therefore patients may present with neuropsychiatric manifestations.
• Acute symptoms include involvement of the central nervous system, skeletal muscle damage, and peripheral nervous system.
• The most significant central nervous system symptoms were dizziness, headache, impaired consciousness, cerebrovascular disease, ataxia, and epilepsy.
• Among the most significant clinical manifestations of the peripheral nervous system, anosmia and dysgeusia are reported.
• Psychiatric disorders that must be considered for their possible presentation are depression, anxiety, stress and psychosis.
• The possibility of the health personnel being affected by the stress of the pandemic and those who suffer from chronic diseases of the nervous system should be foreseen, which can worsen their symptoms and lead to suicide.

Bibliography

  1. Koliatsos, V. E., Wisner-Carlson, R. & Watkins, C. (2020). Neuropsychiatry Definitions, Concepts, and Patient Types. Psychiatr Clin N Am., 43, 213-227.
  2. Shorter, E. (1997). A history of psychiatry: from the era of the asylum to the age of Prozac. New York: John Wiley & Sons. Xii, (p. 436).
  3. Avendano, C. (2002). Neurociencia, neurología, y psiquiatría: Un encuentro inevitable. Rev. Asoc. Esp. Neuropsiq., XXII(83), 65-89.
  4. Lippi, A., Domingues, R., Setz, C., Outeiro, T. F. & Krisko, A. (2020). SARS-CoV-2: at the crossroad between aging and neurodegeneration. Movement Disorders. 2020.
  5. Lahiri, D. & Ardila, A. (2020). COVID-19 Pandemic: A Neurological Perspective. Cureus, 12(4), e7889.
  6. Mao, L., Wang, M., Chen, S., He, Q., Chang, J., Hong, C., et al. (2020). Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. SSRN Journal, 2020.
  7. Baig, A. M., Khaleeq, A., Ali, U. & Syeda, H. (2020). Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci., 11(7), 995-998.
  8. Serrano-Castro, P. J., Estivill-Torrus, G., Cabezudo-Garcia, P., Antonio Reyes-Bueno, J., et al. (2020). Influencia de la infeccion SARS-Cov2 sobre Enfermedades Neurodegenerativas y Neuropsiquiatricas: ¿Una pandemia demorada? Neurolog´ıa.
  9. WHO Cumulative number of reported probable cases of SARS.
  10. Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., et al. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579, 265-269.
  11. Chen, X. & Yu, B. (2020). First two months of the 2019 Coronavirus Disease (COVID-19) epidemic in China: real-time surveillance and evaluation with a second derivative model. Global Health Research and Policy, 5(1), 1-9.
  12. Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., et al. (2020). Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol.
  13. Novel Coronavirus (2019-nCoV) [Internet]. WHO. Report number: 1, 2020.
  14. World Health Organization. Coronavirus disease (COVID-19) pandemic.
  15. Jin, H., Hong, C., Chen, S., Zhou, Y., Wang, Y., Mao, L., et al. (2020). Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke & Vascular Neurology.
  16. Lyden, P. (2020). Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic On Behalf of the AHA/ASA Stroke Council Leadership. Stoke, 51(6), 1910-1912.
  17. Guan, W., Ni, Z., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med., 382, 1708-1720.
  18. Xu, Y. H., Dong, J. H., An, W. M., Lv, X. Y., Yin, X. P., Zhang, J. Z., et al. (2020). Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J Infect, 80(4), 394-400.
  19. Carod-Artal, F. J. (2020). Complicaciones neurológicas por coronavirus y COVID-19. Rev Neurol., 70, 311-322.
  20. Talan, J. (2020). COVID-19: Neurologists in Italy to Colleagues in US: Look for Poorly Dened Neurologic Conditions in Patients with the Coronavirus. Neurology Today.
  21. Zhao, K., Huang, J., Dai, D., Feng, Y., Liu, L. & Nie, S. (2020). Acute myelitis after SARS-CoV-2 infection: a case report. (pp. 1-7).
  22. Poyiadji, N., Shahin, G., Noujaim, D., Stone, M., Patel, S., Grith, B. (2020). COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features. Radiology, 201187.
  23. Marc, D., Dominique, J. F., Élodie, B., et al. (2013). Human Coronavirus: Respiratory Pathogens Revisited as Infectious Neuroinvasive, Neurotropic, and Neurovirulent Agents. CRC Press, 93-122.
  24. Arabi, Y. M., Balkhy, H. H., Hayden, F. G., et al. (2017). Middle East Respiratory Syndrome. N Engl J Med., 376(6), 584-594.
  25. León, R., Bender, J. & Velásquez, L. (2020). Afectación del sistema nervioso por la COVID-19. Anales de la Academia de Ciencias de Cuba., 10(2).
  26. Helms, J., Kremer, S., Merdji, H., et al. (2020). Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med., 382, 2268-2270.
  27. Xinhua.net. Beijing hospital confirms nervous system infections by novel coronavirus.
  28. Moriguchi, T., Harii, N., Goto, J., Harada, D., Sugawara, H., Takamino, J., et al. (2020). A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis., 94, 55-58.
  29. Bender, J., León, R. & Morales, L. (2020). Epilepsia y COVID-19. Anales de la Academia de Ciencias de Cuba., 10(2), especial COVID-19.
  30. Karimi, N., Sharifi, A. & Rouhani, N. (2020). Frequent Convulsive Seizures in an Adult Patient with COVID-19: A Case Report. Iran Red Crescent Med J., 22(3), e102828.
  31. Li, Y., Wang, M., Zhou, Y., Chang, J., Xian, Y., Mao, L., et al. (2020). Acute cerebrovascular disease following COVID-19: a single, retrospective, observational study.
  32. Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., et al. (2020). Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiology.
  33. Bender, J., León, R. & Mendieta, M. (2020). Enfermedad cerebrovascular y COVID-19. Anales de la Academia de Ciencias de Cuba., 10(2), especial COVID-19.
  34. Zhang, Y., Xiao, M., Zhang, S. & Li, Y. (2020). Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. The New England Journal of Medicine. 2020 Massachusetts Medical Society.
  35. Guidon, A. C. & Amato, A. A. (2020). COVID - 19 and neuromuscular disorders. Neurology, 94(22), 959-969.
  36. Association of British Neurologists (2020). Association of British Neurologists guidance on COVID-19 for people with neurological conditions, their doctors and carers. (pp. 1-20).
  37. Butowt, R. & Bilinska, K. (2020). SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection. ACS Chemical Neuroscience, 11, 9, 1200-1203.
  38. León, R., Bender, J. & Velásquez, L. (2020). Disfunción olfatoria y COVID-19. Anales de la Academia de Ciencias de Cuba., 10(2), especial COVID-19.
  39. Menni, C., Valdes, A. M., Freidin, M. B., et al. (2020). Real-time tracking of self-reported symptoms to predict potential COVID-19. Nature Medicine.
  40. Lechien, J. R., Cabaraux, P., Chiesa-Estomba, C. M. & Khalife, M. (2020). Objective olfactory testing in patients presenting with sudden onset olfactory dysfunction as the first manifestation of confirmed COVID-19 infection. (pp. 1-17).
  41. Troyer, E. A., Kohn, J. N. & Hong, S. (2020). Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain, Behavior, and Immunity, 87, 34-39.
  42. Honigsbaum, M. (2013). The art of medicine: “an inexpressible dread”: Psychoses of influenza at fin-de-siècle. Lancet, 381(9871), 988-989.
  43. Menninger, K. A. (1926). Influenza and Schizophrenia. Am. J. Psychiatry., 82, 469-529.
  44. Kim, J. E., Heo, J. H., Kim, H. O., Song, S. H., Park, S. S., Park, T. H., Ahn, J. Y., Kim, M. K. & Choi, J. P. (2017). Neurological complications during treatment of middle east respiratory syndrome. J. Clin. Neurol., 13(3), 227-233.
  45. Manjunatha, N., Math, S. B., Kulkarni, G. B. & Chaturvedi, S. K. (2011). The neuropsychiatric aspects of influenza/swine flu: A selective review. Ind. Psychiatry J., 20(2), 83-90.
  46. Tsai, L. K., Hsieh, S. T., Chao, C. C., Chen, Y. C., Lin, Y. H., Chang, S. C. & Chang, Y. C. (2004). Neuromuscular disorders in severe acute respiratory syndrome. Arch. Neurol., 61(11), 1669-1673.
  47. Wu, H., Zhuang, J., Stone, W. S., Zhang, L., Zhao, Zhengqing, Wang, Z., Yang, Y., Li, X., Zhao, X., Zhao & Zhongxin (2014). Symptoms and occurrences of narcolepsy: A retrospective study of 162 patients during a 10-year period in Eastern China. Sleep Med., 15, 607-613.
  48. Kępińska, A. P., Iyegbe, C. O., Vernon, A. C., Yolken, R., Murray, R. M. & Pollak, T. A. (2020). Schizophrenia and Influenza at the Centenary of the 1918-1919 Spanish Influenza Pandemic: Mechanisms of Psychosis Risk. Front. Psychiatry., 11, 1-19.
  49. Lam, M. H. B. (2009). Mental Morbidities and Chronic Fatigue in Severe Acute Respiratory Syndrome Survivors. Arch. Intern. Med., 169(22), 2142-2147.
  50. Kang, L., Ma, S., Chen, M., Yang, J., Wang, Y., Li, R., Yao, L., Bai, H., Cai, Z., Xiang Yang, B., Hu, S., Zhang, K., Wang, G., Ma, C. & Liu, Z. (2020b). Impact on Mental Health and Perceptions of Psychological Care among Medical and Nursing Staff in Wuhan during the 2019 Novel Coronavirus Disease Outbreak: a Cross-sectional Study. Brain. Behav. Immun., 87, 11-17.
  51. Lai, J., Ma, S., Wang, Y., Cai, Z., Hu, J., Wei, N., Wu, J., Du, H., Chen, T., Li, R., Tan, H., Kang, L., Yao, L., Huang, M., Wang, H., Wang, G., Liu, Z. & Hu, S. (2020). Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019. JAMA Netw., 3(3), e203976.
  52. Lee, S. M., Kang, W. S., Cho, A. R., Kim, T., Park, J. K. (2018). Psychological impact of the 2015 MERS outbreak on hospital workers and quarantined hemodialysis patients. Compr. Psychiatry., 87, 123-127.
  53. Lin, C. Y., Peng, Y. C., Wu, Y. H., Chang, J., Chan, C. H. & Yang, D. Y. (2007). The psychological effect of severe acute respiratory syndrome on emergency department staff. Emerg. Med. J., 24(1), 12-17.
  54. Mealer, M., Burnham, E. L., Goode, C. J., Rothbaum, B. & Moss, M. (2009). The prevalence and impact of post traumatic stress disorder and burnout syndrome in nurses. Depress Anxiety, 26(12), 1118-1126.
  55. Arango, C. (2020). Lessons learned from the coronavirus health crisis in Madrid, Spain: How COVID-19 has changed our lives in the last two weeks. Biological Psychiatry.
  56. American Psychiatric Association (APA). Manual diagnóstico y estadístico de los trastornos mentales. DSM-5. Editorial Médica Panamericana. 2014.
  57. Brooks, S. K., Webster, R. K., Smith, L. E., Woodland, L., Wessely, S., Greenberg, N. & Rubin, G. J. (2020). The psychological impact of quarantine and how to reduce it: rapid review of evidence. Lancet, (395), 912-920.
  58. Pandya, A. (2009). Psiquiatría de adultos en situación de desastre. En FOCUS, APA (Asociación de Psiquiatría Americana) Lifelong learning in Psychiatry. Trastorno por estrés postraumático y Psiquiatría de desastres (I). Washington DC and London, UK, 7-11, 5.
  59. Yao, H., Chen, J. H. & Xu, Y. F. (2020). Patients with mental health disorders in the COVID-19 epidemic. The Lancet Psychiatry, 7(4), PE21.15-16 6.
  60. Peña Koka, X. (2020). Ya se notan los efectos del confinamiento: depresión, estrés, insomnio y ansiedad. El confidencial. 26 marzo 2020.
  61. Arango, C., Díaz-Caneja, C. M., McGorry, P. D., Rapoport, J., Sommer, I. E., Vorstman, J. A., McDaid, D., Marín, O., Serrano-Drozdowskyj, E., Freedman, R. & Carpenter, W. (2018). Preventive strategies for mental health. Lancet Psychiatry, 5(7), 591-604.
  62. Greenberg, N., Docherty, M., Gnanapragasam, S. & Wessely, S. (2020). Managing mental health challenges faced by healthcare workers during covid-19 pandemic. BMJ., 368, m1211.
  63. Brown, A. S. & Derkits, E. J. (2010). Prenatal Infection and Schizophrenia: A Review of Epidemiologic and Translational Studies. Am. J. Psychiatry., 167, 261-280.
  64. Khandaker, G. M., Zimbron, J., Dalman, C., Lewis, G. & Jones, P. B. (2012). Childhood infection and adult schizophrenia: A meta-analysis of population-based studies. Schizophr. Res., 139, 161-168.
  65. Okusaga, O., Yolken, R. H., Langenberg, P., Lapidus, M., Arling, T. A., Dickerson, F. B., Scrandis, D. A., Severance, E., Cabassa, J. A., Balis, T. & Postolache, T. T. (2011). Association of seropositivity for influenza and coronaviruses with history of mood disorders and suicide attempts. J. Affect. Disord., 130, 220-225.
  66. Severance, E. G., Dickerson, F. B., Viscidi, R. P., Bossis, I., Stallings, C. R., Origoni, A. E., Sullens, A. & Yolken, R. H. (2011). Inmunorreactividad del coronavirus en individuos con un inicio reciente de síntomas psicóticos. Schizophr. Toro., 37, 101-107.
  67. Valdes-Florido, M. J., Lopez-Dıaz, A., Palermo-Zeballos, F. J., Martınez-Molina, I., Martın-Gil, V. E., Crespo-Facorro, B. & Ruiz-Veguilla, M. (2020). Reactive psychoses in the context of the COVID-19 pandemic: clinical perspectives from a case series. Revista de psiquiatrıa y salud mental (Barcelona)., 13(2), 90-94.
  68. Rey, P. C. (2020). Manifestaciones neuropsiquiátricas del Covid-19. Departamento de Salud Mental. Hospital de Clinicas "José de San Martín". Facultad de Medicina. Universidad de Buenos Aires.
  69. Brauser, D. (2020). Depresión vinculada a neurodisfunción y lesiones cerebrales en la esclerosis múltiple. Medscape-21 de mayo de 2020.

Total Articles Published

6
7
2


Track Your Article







Highlights


Cient Periodique is a ‘Gold’ open access publisher that aspires to offer absolute free, unrestricted access to the valuable research information

We welcome all the eminent authors to submit your valuable paper

Cient Periodique invites the participation of honourable Editors and Authors

CPQ Journals provide Certificates for publication

Cient Periodique also offers memberships for potential Authors

Best Articles will be appreciated with the provision of corresponding Certificate